XML 86 R65.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENTS, Summarized Financial Information by Segment (Details)
$ in Thousands
 3 Months Ended 12 Months Ended
Apr. 01, 2019
USD ($)
Jun. 30, 2023
USD ($)
Dec. 31, 2024
USD ($)
Facility
Segment
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Segment Reporting Information [Abstract]          
Number of plasma collection facilities under development | Facility     10    
Number of operating segments | Segment     2    
Revenues     $ 426,454 $ 258,215 $ 154,080
Cost of product revenue     206,901 169,273 118,815
Research and development $ 1,000   1,813 3,300 3,614
Plasma center operating expenses   $ 700 4,245 4,266 17,843
Depreciation and amortization expense     8,045 8,332 7,113
Other expense, net     (13,269) (49,871) (26,539)
Income (loss) before taxes     125,714 (28,239) (65,904)
Total assets     488,678 329,182 348,461
Segment Reconciliation [Abstract]          
Consolidated selling, general and administrative expense     74,124 59,020 52,458
Unallocated interest expense, primarily related to interest on senior debt (see Note 7)     (13,930) (25,027) (19,279)
Loss on extinguishment of debt (see Note 7)     (1,243) (26,174) (6,670)
Unallocated interest income     2,097 1,617 45
Operating Segments [Member]          
Segment Reporting Information [Abstract]          
Revenues     426,311 258,072 153,937
Cost of product revenue     206,901 169,273 118,815
Research and development     1,813 3,300 3,614
Plasma center operating expenses     4,245 4,266 17,843
Selling, marketing and distribution     18,683 18,407 13,667
Depreciation and amortization expense     8,045 8,332 7,113
General and administrative expense     26,001 18,625 16,312
Other expense, net     (183)   (85)
Income (loss) before taxes     168,097 43,218 (17,537)
Expenditures for additions to long-lived assets     8,575 4,771 13,911
Total assets     319,774 281,452 275,230
Operating Segments [Member] | ADMA BioManufacturing [Member]          
Segment Reporting Information [Abstract]          
Revenues     415,806 249,738 144,070
Cost of product revenue     195,605 161,157 108,882
Research and development     1,813 3,300 3,614
Plasma center operating expenses     0 0 0
Selling, marketing and distribution     18,683 18,407 13,667
Depreciation and amortization expense     4,827 5,156 4,709
General and administrative expense     26,001 18,625 16,312
Other expense, net     (178)    
Income (loss) before taxes     173,138 47,267 374
Expenditures for additions to long-lived assets     8,352 2,952 5,247
Total assets     289,297 246,719 238,159
Operating Segments [Member] | Plasma Collection Centers [Member]          
Segment Reporting Information [Abstract]          
Revenues     10,505 8,334 9,867
Cost of product revenue     11,296 8,116 9,933
Research and development     0 0 0
Plasma center operating expenses     4,245 4,266 17,843
Selling, marketing and distribution     0 0 0
Depreciation and amortization expense     3,218 3,176 2,404
General and administrative expense     0 0 0
Other expense, net     (5)    
Income (loss) before taxes     (5,041) (4,049) (17,911)
Expenditures for additions to long-lived assets     223 1,819 8,664
Total assets     30,477 34,733 37,071
Reconciling Item [Member]          
Segment Reporting Information [Abstract]          
Revenues     143 143 143
Income (loss) before taxes     143 143 143
Segment Reconciliation [Abstract]          
Unallocated interest expense, primarily related to interest on senior debt (see Note 7)     (13,930) (25,027) (19,276)
Loss on extinguishment of debt (see Note 7)     (1,243) (26,174) (6,670)
Unallocated interest income     2,087 1,589  
Corporate [Member]          
Segment Reporting Information [Abstract]          
General and administrative expense [1]     29,440 21,988 22,479
Income (loss) before taxes [1]     (29,440) (21,988) (22,479)
Total assets     $ 168,904 [2] $ 47,730 [3] $ 73,231 [3]
[1] Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company’s operating segments.
[2] Primarily consists of cash and deferred tax assets.
[3] Primarily consists of cash.